



Bal Raj Bhandari, M.D.
3206 Lake DeSiard Drive
Monroe, LA 71201

[Phone: Home (318) 325-5270; Work (318) 283-2177]

PERSONAL DATA:

DOB: November 1, 1961
Place-of-Birth: Granby, Quebec, Canada
Marital Status: Married

CERTIFICATION:

2003 American Board of Physician Nutrition Specialist
1995 Board Certified, Gastroenterology
1994 U.S. Medical Licensing Exam; Parts 1, 2 and 3
1994 Board Certified, Nutrition
1992 Diplomat American Board of Internal Medicine
1988 Licensing examination of Medical Colleges of Canada

EDUCATION:

September 2003
How to Coordinate Clinical Trials: The Basics
Houston, Texas
July 1, 1992 – June 30, 1995
Fellowship in Gastroenterology and Nutrition – Winthrop University Hospital
Minneola, New York
January 1, 1992 – June 30, 1992
Chief Medical Resident – Our Lady of Mercy Medical Center
Bronx, New York
January 1, 1989 – December 31, 1991



Chief Medical Resident – Our Lady of Mercy Medical Center

Bronx, New York

September 1983 – May 1987

Graduate Medical Education – The University of Ottawa Medical School

Ottawa, Ontario, Canada

September 1978 – May 1983

Undergraduate Education – BSC Chemistry (Honors) – The University of Ottawa

Ottawa, Ontario, Canada

EMPLOYMENT:

2002 – Present

Delta Research Partners, LLC

611 Grammont Street, Monroe, LA 71201

Title: Principal Investigator

1998 – Present

Endoscopy Center

316 South 6th Street, Monroe, LA 71201

Title: Staff Physician

July 1995 – Present

Gastroenterology and Nutritional Medical Services

616 South Washington Street, Bastrop, LA

FACULTY APPOINTMENTS:

July 1992

Preceptor – Introduction to Clinical Medicine – SUNY Health Center at Stony Brook

Stony Brook, New York

January 1992 – July 1992

Chief Medical Resident

1989 – 1992

Assistant Clinical Instructor

HONORS AND AWARDS:

September 1997

Named Spokesperson for the American Liver Foundation in Northeast Louisiana by

Governor M.J. "Mike" Foster

1979, 1980, 1982, 1983:

Dean's List – University of Ottawa: Ottawa, Ontario, Canada

PUBLICATIONS:

1. C. Difficile in a Community Hospital : Badiga, M.; Bhandari, Raj; Pitchimoni, C.S.: *Gastroenterology*, 1991; 100:A405
2. Na-glucose Transport is Impaired in Villus Electrocytes of Chronically Inflamed Rabbit Ileum : C.S. Hyun; L.A. Martello; C.W.P. Chen; Raj Bhandari; S. Teichberg: *Gastroenterology*, 1994; 106:A239
3. Phorbol Ester-Induced Cl Secretion in Rabbit Ileum is Associated with Translocation of PKC-isoform: Raj Bhandari, L.A. Martello, C.S. Hyun: *Gastroenterology*, 1994; 106:A222
4. Combined Treatment with Postnasal drainage: YAG Laser and Absolute Ethanol Injection compared to Nd:YAG Laser Therapy Alone in Malignant Esophageal and Rectal Obstruction: Raj Bhandari, B. Banerjee: submitted to *GI Endoscopy*
5. Current Management of Secretory Diarrhea, A Review: Raj Bhandari; R. Buradoff; accepted for Spring Issue, *The Gastroenterologist*
6. Mechanism of PDG-Induced Cl Secretion in the Distal Rabbit Ileum; R. Bhandari, L. Martello, C.S. Hyun, submitted to *AJP*
7. Alteration of Enterocyte Na-glucose Co-transporter (SGLT-1) in Chronic Inflammation : C. Hyun, R. Bhandari, et al, submitted to *AJP*
8. Chronic Inflammation Induces Alteration in the Zonula Occludens (ZO) and Lateral Junctional Strands of Mucosal Epithelial Cells in Rabbit Ileum : C.S. Hyun, R. Bhandari, et al, submitted as abstract to *Gastroenterology*, 1995.
9. Protein Kinase-C (PKC)-Medicated Chloride Secretion is Cl/HCO₃-Dependent in Rabbit Ileum : R. Bhandari, C. Hyun, submitted as abstract to *Gastroenterology*, 1995



PRESENTATION:

1992 - 1995

Staff - Lecturer-Core Lecture Series to the House - Winthrop University Hospital
Minneola, New York

1992

Medical Grand Rounds - Our Lady of Mercy Medical Center
Bronx, New York

AFFILIATION:

American Board of Physician Nutrition Specialists
American Gastroenterology Association
American Society of Gastrointestinal Endoscopy
American College of Physicians

RESEARCH EXPERIENCE:

2008 Clinical Studies:

1. A multi-center, randomized, controlled study to investigate the safety dose of intravenous Ferric Carboxymaltose (FCM) vs. Standard Medical Care in treating Iron Deficiency Anemia in subjects who are not Dialysis dependant.
2. A multi-center, randomized, controlled study to investigate the safety and tolerability of Intravenous Ferric Carboxymaltose (FCM) vs. Standard Medical Care in treating Iron Deficiency Anemia
3. A Phase 2 multi-center, randomized, placebo-controlled, double-blind study to evaluate the Safety and Efficacy of Golimumab maintenance therapy, administered subcutaneously, in subjects with moderately to severely active Ulcerative Colitis.
4. A Phase 3 multi-center, randomized, placebo-controlled, double-blind study to evaluate the Safety and Efficacy of Golimumab maintenance therapy, administered subcutaneously, in subjects with moderately to severely active Ulcerative Colitis.



5. A Safety and efficacy evaluation of BLI850 vs. HalfLytely® and Bisacodyl Bowel prep kit as Bowel Cleansing preparation in adult subjects.
6. A phase IIIb, multinational, randomized, double-blind, placebo-controlled trial to assess the efficiency and safety of certolizumab pegol, a pegylated Fab' fragment of a humanized anti-TNF-alpha monoclonal antibody, administered subcutaneously at weeks 0,2 and 4 in subjects with moderately to severely active Crohn's disease.
7. A phase IIIb, multinational, open-label, follow-on trial to C87085 designed to assess the long-term safety of certolizumab pegol, a pegylated Fab' fragment of a humanized anti-TNF-alpha monoclonal antibody, administered at weeks 0,2,and 4, and then every 4 weeks thereafter, in subjects with moderately to severely active Crohn's disease who have participated in study C87085.
8. A randomized, double-blind, placebo-controlled study of AGI-003 (Averapamil) in the treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D).
9. A open-label, roll-over safety study of AGI-003 (Averapamil) in the treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D)
10. A phase 3, randomized, double-blinded, placebo-controlled, multi-center study to assess the efficacy and safety of Rifaximin 550mg TID in the treatment of subjects with Non-Constipation Irritable Bowel Syndrome
11. A multi-center, randomized, placebo-controlled, double-blinded study of the efficacy and safety of Lubiprostone in patients with Opioid-induced bowel dysfunction.
12. Validation of patient-reported outcome measures for the assessment of GERD symptoms and their subsequent impact on patients with a partial response to PPI treatment in a two part multi-center phase IIA study including a four week randomized double-blind, placebo-controlled parallel-group treatment period with AZD3355, 65 mg BID as add-on treatment of PPI.
13. A phase 3, randomized, double blinded, placebo-controlled, parallel-group Trial of Linaclotide administered orally for 12 weeks followed by a 4-week randomized withdrawal period in patients with Chronic Constipation.
14. An Open-label, long term safety study of oral Linaclotide administered to patients with Chronic Constipation or Irritable Bowel Syndrome with Constipation.



2007 Clinical Studies:

1. A multi-center, randomized, controlled study to investigate the safety dose of intravenous Ferric Carboxymaltose (FCM) vs. Standard Medical Care in treating Iron Deficiency Anemia in subjects who are not Dialysis dependant.
2. A multi-center, randomized, controlled study to investigate the safety and tolerability of intravenous Ferric Carboxymaltose (FCM) vs. Standard Medical Care in treating Iron Deficiency Anemia
3. A Phase 2 multi-center, randomized, placebo-controlled, double-blind study to evaluate the Safety and Efficacy of Golimumab maintenance therapy, administered subcutaneously, in subjects with moderately to severely active Ulcerative Colitis.
4. A Phase 3 multi-center, randomized, placebo-controlled, double-blind study to evaluate the Safety and Efficacy of Golimumab maintenance therapy, administered subcutaneously, in subjects with moderately to severely active Ulcerative Colitis.
5. A Safety and efficacy evaluation of BLI850 vs. HalfLytely® and Bisacodyl Bowel prep kit as Bowel Cleansing preparation in adult subjects.
6. A phase IIIb, multinational, randomized, double-blind, placebo-controlled trial to assess the efficiency and safety of certolizumab pegol, a pegylated Fab' fragment of a humanized anti-TNF-alpha monoclonal antibody, administered subcutaneously at weeks 0,2 and 4 in subjects with moderately to severely active Crohn's disease.
7. A phase IIIb, multinational, open-label, follow-on trial to C87085 designed to assess the long-term safety of certolizumab pegol, a pegylated Fab' fragment of a humanized anti-TNF-alpha monoclonal antibody, administered at weeks 0,2,and 4, and then every 4 weeks thereafter, in subjects with moderately to severely active Crohn's disease who have participated in study C87085.
8. A randomized, double-blind, placebo-controlled study of AGI-003 (Averapamil) in the treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D).
9. A open-label, roll-over safety study of AGI-003 (Averapamil) in the treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D)



10. A phase 3, randomized, double-blinded, placebo-controlled, multi-center study to assess the efficacy and safety of Rifaximin 550mg TID in the treatment of subjects with Non-Constipation Irritable Bowel Syndrome
11. A multi-center, randomized, placebo-controlled, double-blinded study of the efficacy and safety of Lubiprostone in patients with Opioid-induced bowel dysfunction.
12. Validation of patient-reported outcome measures for the assessment of GERD symptoms and their subsequent impact on patients with a partial response to PPI treatment in a two part multi-center phase IIA study including a four week randomized double-blind, placebo-controlled parallel-group treatment period with AZD3355, 65 mg BID as add-on treatment of PPI.
13. A phase 3, randomized, double blinded, placebo-controlled, parallel-group Trial of Linaclotide administered orally for 12 weeks followed by a 4-week randomized withdrawal period in patients with Chronic Constipation.
14. An Open-label, long term safety study of oral Linaclotide administered to patients with Chronic Constipation or Irritable Bowel Syndrome with Constipation.
15. A randomized, double-blind, placebo-controlled multicenter Phase II/III study to evaluate the efficacy and safety of tegaserod and placebo given orally for 12 weeks for the treatment of Opioid-Induced Constipation in patients with Chronic Non-Cancer Pain.
16. A 52-week extension to study CHTF919N2201 to evaluate the safety and efficacy of tegaserod (6mg BID and 12mg BID OD) given orally for the treatment of Opioid-Induced Constipation in patients with Chronic Non-Chronic Pain.
17. A randomized, double-blind, placebo-controlled, multicenter evaluation of the efficacy and safety of tegaserod 6mg BID administered orally for 12 weeks, to patients with Chronic Constipation, aged 65 or older.

2006 Clinical Studies:

1. Comparison of weight-based doses of Taribavirin combined with peginterferon Alfa-2b versus Rivavirin combined with pefingterferon Alfa-2b in therapy-naïve patients with Chronic Hepatitis C Virus Genotype 1 Infection.
2. Non-responsive to prior therapy and Pegylated Interferon Alfa and Ribavirin.
3. The safety and efficacy of hematinic agent in the treatment of Postpartum patients.



2005 Clinical Studies:

1. A 12-week, multicenter, double-blind, randomized efficacy and safety study of LUBIPROSTONE in subjects with constipation-predominant Irritable Bowel Syndrome.
2. A randomized, double-blind, dose-response study to assess the efficacy and safety of AQUAVAN Injection for procedural sedation in patients undergoing colonoscopy.
3. A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of ITOPRIDE HCl in patients suffering from functional dyspepsia.
4. A multicenter, open-label study to evaluate the long-term safety and efficacy of ITOPRIDE HCl in patients suffering from functional dyspepsia.
5. A multicenter, randomized, blinded, placebo controlled, cross-over study to investigate the safety and tolerability of intravenous VIT-45 in patients with Iron Deficiency Anemia.
6. A Phase II randomized, double-blind, placebo controlled, parallel group, multicenter study to evaluate the efficacy and safety of a four-week treatment with ATI-7505 for the healing of acute erosive esophagitis.
7. A Phase II randomized, double-blind, placebo controlled, parallel group, multicenter study to evaluate the efficacy and safety of a four-week treatment with ATI-7505 for the relief of heartburn symptoms in patients with symptomatic Gastroesophageal Reflux Disease (GERD)-Amendment 1.

2004 Clinical Studies:

1. Aquavan Injection: A Phase III, randomized, open-label study to assess the safety and efficacy of AQUAVAN Injection versus Midazolam HCl for sedation in patients undergoing colonoscopy procedures.
2. A Phase 2b study of merimepodib in combination with pegylated interferon alfa-2a (Pegasys) and Ribavirin in subjects with chronic genotype I hepatitis-C non-responsive to prior therapy with pegylated interferon alfa and ribavirin.
3. A Phase 2b multicenter, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study of YM443 in subjects with functional dyspepsia
4. A 12-week, randomized, double-blind, placebo-controlled study with PRN BID and fixed dosing regimens of Alosetron in Female Subjects with severe diarrhea-predominant irritable bowel syndrome who have failed conventional therapy.

September 2003

How to Coordinate Clinical Trials: The Basics
Houston, Texas

Co-Investigator of three Hepatitis-C Studies:

1. Dr. Ira Jacobson study: Comparison of PEG Interferon Alfa-2B plus Ribavirin given as a fixed dose for on a weight optimized basis for treatment of chronic hepatitis-C in previously untreated adult subjects.
2. A randomized multi-center trial comparing induction PEG-Intron-A plus Ribavirin versus PEG Intron-A plus Ribavirin in patients who have previously not responded or have relapsed following Intron-A based therapy for chronic hepatitis-C, with maintenance therapy for patients who continue to remain non-responsive. Principal investigator: Eric Lawiz, M.D., Gastroenterology Clinic, Brooke Army Medical Center.
3. Consultant for Rebetrone Compliance Assessment Program Survey (the "ReCAP Survey") being conducted by Ingenix Pharmaceutical Services for Schering Corporation.

Investigator:

- 1 Limited access protocol for the use of oral cisapride in the treatment of refractory gastroesophageal reflux disease (GERD) and other gastrointestinal motility disorders

REFERENCES: Available upon request